Cargando…

Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy

In Colorectal cancer (CRC), adenomatous polyposis coli (APC) directly interacts with the Rho guanine nucleotide exchange factor 4 (Asef) and releases its GEF activity. Activated Asef promotes the aberrant migration and invasion of CRC cell through a CDC42-mediated pathway. Knockdown of either APC or...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiuyan, Zhong, Jie, Zhang, Qiufen, Feng, Li, Zheng, Zhen, Zhang, Jian, Lu, Shaoyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100458/
https://www.ncbi.nlm.nih.gov/pubmed/33968990
http://dx.doi.org/10.3389/fmolb.2021.662579
_version_ 1783688793900974080
author Yang, Xiuyan
Zhong, Jie
Zhang, Qiufen
Feng, Li
Zheng, Zhen
Zhang, Jian
Lu, Shaoyong
author_facet Yang, Xiuyan
Zhong, Jie
Zhang, Qiufen
Feng, Li
Zheng, Zhen
Zhang, Jian
Lu, Shaoyong
author_sort Yang, Xiuyan
collection PubMed
description In Colorectal cancer (CRC), adenomatous polyposis coli (APC) directly interacts with the Rho guanine nucleotide exchange factor 4 (Asef) and releases its GEF activity. Activated Asef promotes the aberrant migration and invasion of CRC cell through a CDC42-mediated pathway. Knockdown of either APC or Asef significantly decreases the migration of CRC cells. Therefore, disrupting the APC-Asef interaction is a promising strategy for the treatment of invasive CRC. With the growth of structural information, APC-Asef inhibitors have been designed, providing hope for CRC therapy. Here, we will review the APC-Asef interaction in cancer biology, the structural complex of APC-Asef, two generations of peptide inhibitors of APC-Asef, and small molecule inhibitors of APC-Asef, focusing on research articles over the past 30 years. We posit that these advances in the discovery of APC-Asef inhibitors establish the protein-protein interaction (PPI) as targetable and provide a framework for other PPI programs.
format Online
Article
Text
id pubmed-8100458
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81004582021-05-07 Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy Yang, Xiuyan Zhong, Jie Zhang, Qiufen Feng, Li Zheng, Zhen Zhang, Jian Lu, Shaoyong Front Mol Biosci Molecular Biosciences In Colorectal cancer (CRC), adenomatous polyposis coli (APC) directly interacts with the Rho guanine nucleotide exchange factor 4 (Asef) and releases its GEF activity. Activated Asef promotes the aberrant migration and invasion of CRC cell through a CDC42-mediated pathway. Knockdown of either APC or Asef significantly decreases the migration of CRC cells. Therefore, disrupting the APC-Asef interaction is a promising strategy for the treatment of invasive CRC. With the growth of structural information, APC-Asef inhibitors have been designed, providing hope for CRC therapy. Here, we will review the APC-Asef interaction in cancer biology, the structural complex of APC-Asef, two generations of peptide inhibitors of APC-Asef, and small molecule inhibitors of APC-Asef, focusing on research articles over the past 30 years. We posit that these advances in the discovery of APC-Asef inhibitors establish the protein-protein interaction (PPI) as targetable and provide a framework for other PPI programs. Frontiers Media S.A. 2021-04-22 /pmc/articles/PMC8100458/ /pubmed/33968990 http://dx.doi.org/10.3389/fmolb.2021.662579 Text en Copyright © 2021 Yang, Zhong, Zhang, Feng, Zheng, Zhang and Lu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Yang, Xiuyan
Zhong, Jie
Zhang, Qiufen
Feng, Li
Zheng, Zhen
Zhang, Jian
Lu, Shaoyong
Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title_full Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title_fullStr Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title_full_unstemmed Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title_short Advances and Insights of APC-Asef Inhibitors for Metastatic Colorectal Cancer Therapy
title_sort advances and insights of apc-asef inhibitors for metastatic colorectal cancer therapy
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100458/
https://www.ncbi.nlm.nih.gov/pubmed/33968990
http://dx.doi.org/10.3389/fmolb.2021.662579
work_keys_str_mv AT yangxiuyan advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT zhongjie advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT zhangqiufen advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT fengli advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT zhengzhen advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT zhangjian advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy
AT lushaoyong advancesandinsightsofapcasefinhibitorsformetastaticcolorectalcancertherapy